CLINICAL_TRIALS
trial_result
· 2013-01-30
Clinical Trial Update: Treatment Interruption of Natalizumab [Phase 2]
Summary
A Phase 2 trial evaluating interruption of natalizumab therapy in relapsing-remitting multiple sclerosis has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2013-01-30